文献速递肺血管病与心包/心肌炎血脂与心血管预防

血脂与降脂药靶基因与腹主动脉瘤风险的孟德尔随机化荟萃分析

Genetic Association of Lipids and Lipid Drug Targets With Abdominal Aortic Aneurysm: A Meta-analysis.
PubMed 文献 · JAMA Cardiol · 2018-01-01

该研究利用脂质相关SNP构建遗传风险评分,采用孟德尔随机化方法在国际腹主动脉瘤全基因组关联研究数据中分析血脂与腹主动脉瘤风险的关联。HMGCR、CETP和PCSK9位点变异与腹主动脉瘤风险的关联支持降LDL-C作为潜在防治策略。

要点

  • 遗传性LDL-C每升高1个标准差,腹主动脉瘤风险增加(OR 1.66)。
  • 遗传性HDL-C每升高1个标准差,腹主动脉瘤风险降低(OR 0.67)。
  • HMGCR和CETP位点变异与腹主动脉瘤风险关联支持降脂治疗潜力。

核心结论

  • 孟德尔随机化分析支持血脂在腹主动脉瘤病因中起重要作用。
  • 以药物靶点为代理的遗传变异分析支持降LDL-C是预防和管理腹主动脉瘤的潜在有效策略。

研究设计与样本

  • 研究构建脂质性状相关SNP的遗传风险评分,采用逆方差加权孟德尔随机化及国际腹主动脉瘤GWAS数据进行分析。
  • 敏感性分析包括MR-Egger和加权中位数MR,多变量MR用于检验血脂与腹主动脉瘤风险的独立关联。
  • 数据收集时间为2015年1月9日至2016年1月4日,数据分析时间为2015年1月4日至2016年12月31日。

主要发现

  • 遗传性LDL-C每升高1个标准差与腹主动脉瘤风险增加相关(OR 1.66;95%CI 1.41-1.96;P=1.1×10^-9)。
  • 遗传性HDL-C每升高1个标准差与腹主动脉瘤风险降低相关(OR 0.67;95%CI 0.55-0.82;P=8.3×10^-5)。
  • 遗传性甘油三酯每升高1个标准差与腹主动脉瘤风险增加相关(OR 1.69;95%CI 1.38-2.07;P=5.2×10^-7)。
  • 多变量MR及MR-Egger和加权中位数MR方法中,各脂质组分与腹主动脉瘤风险的关联基本不变。
  • HMGCR的rs12916降LDL-C等位基因与腹主动脉瘤风险相关(OR 0.93;95%CI 0.89-0.98;P=.009)。

关键数值与推荐

  • 遗传风险评分基于脂质性状相关SNP,暴露为遗传性LDL-C、HDL-C和甘油三酯升高。
  • 药物靶点SNP分析涉及HMGCR、CETP和PCSK9基因位点。

临床怎么用

  • 遗传学证据提示降低LDL-C可能有助于预防和管理腹主动脉瘤。
  • 针对HMGCR、CETP和PCSK9的遗传变异分析支持这些靶点作为腹主动脉瘤防治的潜在方向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Risk factors for abdominal aortic aneurysm (AAA) are largely unknown, which has hampered the development of nonsurgical treatments to alter the natural history of disease. OBJECTIVE: To investigate the association between lipid-associated single-nucleotide polymorphisms (SNPs) and AAA risk. DESIGN, SETTING, AND PARTICIPANTS: Genetic risk scores, composed of lipid trait-associated SNPs, were constructed and tested for their association with AAA using conventional (inverse-variance weighted) mendelian randomization (MR) and data from international AAA genome-wide association studies. Sensitivity analyses to account for potential genetic pleiotropy included MR-Egger and weighted median MR, and multivariable MR method was used to test the independent association of lipids with AAA risk. The association between AAA and SNPs in loci that can act as proxies for drug targets was also assessed. Data collection took place between January 9, 2015, and January 4, 2016. Data analysis was conducted between January 4, 2015, and December 31, 2016. EXPOSURES: Genetic elevation of low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG). MAIN OUTCOMES AND MEASURES: The association between genetic risk scores of lipid-associated SNPs and AAA risk, as well as the association between SNPs in lipid drug targets (HMGCR, CETP, and PCSK9) and AAA risk. RESULTS: Up to 4914 cases and 48 002 controls were included in our analysis. A 1-SD genetic elevation of LDL-C was associated with increased AAA risk (odds ratio [OR], 1.66; 95% CI, 1.41-1.96; P = 1.1 × 10-9). For HDL-C, a 1-SD increase was associated with reduced AAA risk (OR, 0.67; 95% CI, 0.55-0.82; P = 8.3 × 10-5), whereas a 1-SD increase in triglycerides was associated with increased AAA risk (OR, 1.69; 95% CI, 1.38-2.07; P = 5.2 × 10-7). In multivariable MR analysis and both MR-Egger and weighted median MR methods, the association of each lipid fraction with AAA risk remained largely unchanged. The LDL-C-reducing allele of rs12916 in HMGCR was associated with AAA risk (OR, 0.93; 95% CI, 0.89-0.98; P = .009). The HDL-C-raising allele of rs3764261 in CETP was associated with lower AAA risk (OR, 0.89; 95% CI, 0.85-0.94; P = 3.7 × 10-7). Finally, the LDL-C-lowering allele of rs11206510 in PCSK9 was weakly associated with a lower AAA risk (OR, 0.94; 95% CI, 0.88-1.00; P = .04), but a second independent LDL-C-lowering variant in PCSK9 (rs2479409) was not associated with AAA risk (OR, 0.97; 95% CI, 0.92-1.02; P = .28). CONCLUSIONS AND RELEVANCE: The MR analyses in this study lend support to the hypothesis that lipids play an important role in the etiology of AAA. Analyses of individual genetic variants used as proxies for drug targets support LDL-C lowering as a potential effective treatment strategy for preventing and managing AAA.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Harrison SC, Holmes MV, Burgess S, et al. Genetic Association of Lipids and Lipid Drug Targets With Abdominal Aortic Aneurysm: A Meta-analysis. JAMA Cardiol. 2018. PMID: 29188294. doi:10.1001/jamacardio.2017.4293

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。